Researchers identify protein “signature” of severe COVID-19
These findings could help researchers identify the mechanisms that cause severe disease.
About Michael Filbin, MD, MS
Dr. Michael Filbin, attending physician in the department of emergency medicine at Massachusetts General Hospital, received his MD from Baylor College of Medicine. He completed a residency in the Harvard Affiliated Emergency Medicine Residency Program (HAEMR) at Brigham and Women's and Massachusetts General Hospitals. Dr. Filbin attends full-time in the Emergency Department and is the Director of Clinical Research in Emergency Medicine. Dr. Filbin's research expertise is sepsis and severe infection.
Clinical Interests:
- Acute Emergency Care
- Sepsis and Septic Shock
Treats:
- Adult & Pediatrics
Locations
Mass General Emergency Medicine
55 Fruit St.
Boston, MA 02115
Phone: 617-724-4100
Medical Education
- MD, Baylor College Of Medicine
- Residency, Brigham and Women's Hospital
American Board Certifications
- Emergency Medicine, American Board of Emergency Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Health Care
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Filbin's interest focuses on early identification, characterization, and management of infection and sepsis. Dr. Filbin was site investigator and co-author on a practice-changing interventional trial in sepsis that aimed to validate protocolized goal-directed therapy with and without invasive monitoring versus standard of care (Protocolized Care for Early Septic Shock – Process ). This trial focused global attention on early sepsis detection as the potential key to making a difference in sepsis outcomes. Dr. Filbin was instrumental in conducting two related NIH-funded studies that both sought to characterize circulating serum protein profiles associated with short- and long-term outcomes (Endothelial Cell Signaling and Microcirculation in Sepsis and Protocolized Goal-directed Resuscitation of Septic Shock to Prevent Acute Kidney Injury - ProGReSS-AKI). Dr. Filbin recently co-authored a large multicenter trial investigating the role of procalcitonin in reducing antibiotic utilization in respiratory infections, and led MGH as the top enroller (Procalcitonin Antibiotic Consensus Trial – ProACT). Dr. Filbin currently coordinates enrollment at MGH in the Emergency Department for the PETAL Network trials (Prevention and Early Treatment of Acute Lung Injury).